Compare W & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | W | HALO |
|---|---|---|
| Founded | 2002 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.7B | 12.0B |
| IPO Year | 2014 | 2001 |
| Metric | W | HALO |
|---|---|---|
| Price | $98.61 | $114.35 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 28 | 11 |
| Target Price | ★ $105.82 | $78.64 |
| AVG Volume (30 Days) | ★ 1.9M | 1.9M |
| Earning Date | 04-30-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 39.15 | N/A |
| EPS | N/A | ★ 3.11 |
| Revenue | N/A | ★ $151,862,000.00 |
| Revenue This Year | $7.39 | $28.24 |
| Revenue Next Year | $6.00 | $12.56 |
| P/E Ratio | ★ N/A | $37.05 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $55.60 | $61.23 |
| 52 Week High | $119.98 | $116.85 |
| Indicator | W | HALO |
|---|---|---|
| Relative Strength Index (RSI) | 46.82 | 66.88 |
| Support Level | $96.49 | $104.49 |
| Resistance Level | $107.91 | N/A |
| Average True Range (ATR) | 4.32 | 3.09 |
| MACD | -0.49 | -0.05 |
| Stochastic Oscillator | 21.98 | 81.05 |
Wayfair engages in e-commerce in the United States (88% of 2025 sales), Canada, the United Kingdom, and Ireland. It's also embarked on expansion into the brick-and-mortar landscape, with 13 stores (excluding outlets) between the AllModern, Birch Lane, Joss & Main, and Wayfair banners. At the end of 2025, the firm offered more than 40 million products from more than 20,000 suppliers under the brands Wayfair, Joss & Main, AllModern, Birch Lane, and Perigold. Its offerings include furniture, everyday and seasonal decor, decorative accents, housewares, as well as advertising and logistics services. Wayfair was founded in 2002 and began trading publicly in 2014.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.